ORKA Oruka Therapeutics, Inc.

NASDAQ
$99.24

Oruka Therapeutics, Inc. (ORKA) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.78 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.6% since its last earnings release on November 9, 2026.

Oruka Therapeutics Beat Consensus Estimates
Monday, November 9, 2026 · 4:04 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · After Close
Earnings Whisper
-
vs ($0.78)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $106.29

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Oruka Therapeutics, Inc.

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.